Silo Pharma, Inc. (SILO) stock
Close on Nov 12, 2026Market cap $3.03MP/E –Yield –
Silo Pharma, Inc. saw revenue fall 25.0% to $54.08K over the twelve months to Jun 30, 2026. At the latest close the market valued the company at $3.03M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $3.03M
- P/E ratio
- –
- Price to sales
- 56.10
- Price to book
- 0.62
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $54.08K
- Net income
- -$4.47M
- EPS, diluted
- -$7.50
- Book value per share
- $4.45
- Diluted shares
- 1M
Trading
- Previous close
- $1.84
- Open
- $1.90
- Day's range
- $1.76 – $1.95
- Volume
- 65,066
- Average volume (20 days)
- 39,794
- Beta (5 years)
- 0.46
- 52-week range
- $1.10 – $10.42
- RSI (14 days)
- 69.6
- Volatility (1 year)
- 113.2%
- Relative volume
- 0.94×
- WACC
- 7.4%
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | SILO | S&P 500 | Difference | SILO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +28.2% | -2.7% | +30.9 pts | ||
| 3 months | -38.3% | -1.7% | −36.5 pts | ||
| Year to date | -62.5% | +11.9% | −74.4 pts | ||
| 1 year | -71.8% | +12.0% | −83.8 pts | ||
| 3 years | -90.6% | +78.2% | −168.8 pts | -54.6% | +21.2% |
| 5 years | -98.8% | +73.2% | −172.0 pts | -58.4% | +11.6% |
Fourteen years at a glance
Fiscal years 2010 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Press releases
Releases Silo Pharma filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- News
- News
- News
About Silo Pharma
Pharmaceutical Preparations
Silo Pharma, Inc. is a developmental-stage biopharmaceutical and cryptocurrency company. In its therapeutics business, the company develops conventional drugs and psychedelic formulations targeting underserved conditions, including post-traumatic stress disorder, stress-induced anxiety disorders, fibromyalgia, and central nervous system diseases. Its product pipeline features candidates such as SPC-15, an intranasal prophylactic therapy; SP-26, a time-release ketamine implant; SPC-14 for Alzheimer’s disease; and SPU-16 for neuroinflammatory conditions like multiple sclerosis. Its digital asset treasury operations focus on acquiring and staking major cryptocurrencies such as Bitcoin, Ethereum, and Solana to generate yield. The company's customer base consists of patients suffering from psychiatric, chronic pain, and neurological disorders, as well as the broader healthcare and medical community.
Company profile, executives and historySilo Pharma stock: common questions
What is Silo Pharma's stock price?
SILO closed at $1.91 on Nov 12, 2026, up 3.69% on the day. Over the past 52 weeks it traded between $1.10 and $10.42.
What is Silo Pharma's market cap?
Silo Pharma was worth $3.03M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is SILO's P/E ratio?
Silo Pharma lost money over fiscal 2025 (diluted EPS -$7.50), so it has no meaningful P/E ratio.
How much revenue does Silo Pharma make?
Silo Pharma reported revenue of $54.08K for the twelve months to Jun 30, 2026, down 25.0% from a year earlier.
Does Silo Pharma pay a dividend?
No. Silo Pharma has not paid a cash dividend over the last twelve months.
How has SILO stock performed over the past year?
Including dividends, SILO returned -71.8% over the past year, against +12.0% for the S&P 500.
How many SILO shares are sold short?
0M shares were sold short at the latest FINRA report, 1.01% of the float, or 1.1 days of average trading volume.
Who are Silo Pharma's competitors?
Companies most similar to Silo Pharma by business, industry and size include IXHL, ASBP, AVTX, LNAI, ADXN.
See a number that looks wrong?